Industry, FDA Agree On Draft User Fee Commitment Letter
This article was originally published in The Gray Sheet
Draft commitment and legislative language come one month after agreement “in principle” on MDUFA III reauthorization.
You may also be interested in...
To enhance combination product reviews, drug-fee revenue will pay for related positions in the agency's Center for Devices and Radiological Health.
To enhance combination product reviews, drug fee revenue will pay for related positions in CDRH.
FDA plans to exempt an array of class II and class I medical devices from premarket submission requirements because the devices are sufficiently well understood and do not present risks that require premarket notification review to assure their safety and effectiveness.